Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
102189 trials found · Page 164 of 5110
-
New hope for tough esophageal cancer: phase 3 trial launches
Disease control Recruiting nowThis study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune che…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
Your own stem cells could save your hip from collapse
Disease control Recruiting nowThe commercial decalcified bone scaffold combined with the patient's autologous bone marrow mesenchymal stem cells was used for in vitro culture to form tissue-engineered bone, and the effect of this tissue-engineered bone in early non-traumatic femoral head necrosis was explored…
Phase: NA • Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Disease control
Last updated Jun 08, 2026 13:10 UTC
-
New dengue drug trial aims to knock out virus faster
Disease control Recruiting nowThis is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection * Primary objectives: * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection …
Phase: PHASE2 • Sponsor: Oxford University Clinical Research Unit, Vietnam • Aim: Disease control
Last updated Jun 02, 2026 11:59 UTC
-
Grow your own knee cartilage: stem cell breakthrough trial
Disease control Recruiting nowThe joint cartilage constructed by combining bone marrow mesenchymal stem cells with three-dimensional materials has achieved the goal of repairing joint cartilage.
Phase: NA • Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Disease control
Last updated Jun 03, 2026 12:02 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Not yet recruitingThis study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoemb…
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC
-
Engineered immune cells target abdominal tumors in new cancer trial
Disease control Recruiting nowTo find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 22:23 UTC
-
New drug cocktail shows promise for tough head and neck cancers
Disease control Recruiting nowThis is a randomized controlled, phase II clinical study designed to explore the efficacy and safety of nimotuzumab combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The primary endpoint of…
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 03, 2026 12:07 UTC
-
New drug cocktail shows promise for tough head and neck cancers
Disease control ENROLLING_BY_INVITATIONThis is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck squamous cell carcinoma (HNSCC) who have progressed afte…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
App aims to boost HIV prevention in young men who have sex with men
Prevention Recruiting nowMyPEEPS Mobile Plus, a multi-level intervention for improving HIV prevention outcomes in YMSM, is a novel and evidence-driven approach using mobile technology to deliver HIV prevention information specifically developed for YMSM. Building on strong preliminary work, the proposed …
Phase: NA • Sponsor: Columbia University • Aim: Prevention
Last updated Jun 05, 2026 12:10 UTC
-
New hope for liver cancer patients when first-line therapy fails
Disease control Not yet recruitingThis prospective, single-arm, multicenter Phase II clinical trial aims to evaluate the efficacy and safety of Benmelstobart plus anlotinib combined with SBRT in patients with oligometastatic hepatocellular carcinoma who have failed first-line targeted therapy. Key study questions…
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New hope for prediabetes: drug combo aims to turn back the clock
Disease control Not yet recruitingThis multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Chiglitazar Sodium combined with lifestyle intervention for reversing prediabetes to normal glucose metabolism. Eligible participants with prediabetes will be randomiz…
Phase: NA • Sponsor: Second Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 04, 2026 11:02 UTC
-
New cocktail of drugs shows promise for tough breast cancer
Disease control Recruiting nowThis study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for advanced triple-negative breast cancer. A total of 34 pa…
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
New combo therapy aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as suitable for D2 radical surgery and capable of R0 resec…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Could a vitamin boost beat TB faster?
Disease control Recruiting nowThe purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.
Phase: PHASE2 • Sponsor: Gates Medical Research Institute • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC
-
New eye drug aims to block two causes of vision loss in wet AMD
Disease control Not yet recruitingOculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States (US), the Europea…
Phase: PHASE2, PHASE3 • Sponsor: Shenzhen Oculgen Biomedical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
New drug asciminib aims to control CML in german patients
Disease control Recruiting nowThe aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibito…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 02, 2026 11:56 UTC
-
New shot could soothe severe eczema in teens
Disease control Not yet recruitingThis is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Phase: PHASE3 • Sponsor: Shanghai Mabgeek Biotech.Co.Ltd • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New hope for stomach cancer patients with abdominal spread: targeted combo therapy enters phase 2 trial
Disease control Recruiting nowIn this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New hope for advanced liver cancer: targeted drug aims to shrink tumors
Disease control Recruiting nowThis study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New immunotherapy combo aims to stop colorectal cancer relapse
Disease control Recruiting nowThe NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (im…
Phase: PHASE2 • Sponsor: NSABP Foundation Inc • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC